Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TET2 | Q6N021 | 3/20 | 0.52 |
| ▸ | KDM4A | O75164 | 2/20 | 0.52 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.52 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.52 |
| ▸ | TET3 | O43151 | 1/20 | 0.52 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3261082 | 0.85 | TET2 (0.67) | TET2KDM4AKDM4CKDM2ATET3 | |
| SCHEMBL6054264 | 0.85 | TET2 (0.67) | TET2KDM4AKDM4CKDM2ATET3 | |
| SCHEMBL16600445 | 0.84 | GPR84 (0.58) | TET2KDM4AKDM4CKDM2ATET3 | |
| SCHEMBL14661635 | 0.83 | TET2 (0.52) | TET2KDM4AKDM4CKDM2ATET3 | |
| SCHEMBL406554 | 0.83 | TET2 (0.52) | TET2KDM4AKDM4CKDM2ATET3 | |
| SCHEMBL9515485 | 0.83 | TET2 (0.52) | TET2KDM4AKDM4CKDM2ATET3 | |
| SCHEMBL6381204 | 0.80 | GABRR1 (0.59) | TP53ALDH1A1GABRR1CYP1A2 | |
| SCHEMBL19815026 | 0.80 | TP53 (0.47) | TET2KDM4AKDM4CKDM2ATET3 | |
| SCHEMBL16600629 | 0.79 | TET2 (0.48) | TET2KDM4AKDM4CKDM2ATET3 | |
| SCHEMBL11535131 | 0.79 | TET2 (0.48) | TET2KDM4AKDM4CKDM2ATET3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103209973-B | Lactyllactate/salt synthesis using dilactide | CARAVAN INGREDIENTS INC. (US) | 2015-11-25 | — | — | CN | claimed |
| CN-103209973-A | Lactyllactate/salt synthesis using dilactide | CARAVAN INGREDIENTS INC | 2013-07-17 | — | — | CN | claimed |
| EP-0249222-B1 | RADIATION CURABLE RESIN | Toyo Boseki Kabushiki Kaisha (JP) | 1993-01-20 | — | — | EP | claimed |
| US-4734480-A | MAGNETIC TAPES, ACRYLATED POLYURETHANES | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 1988-03-29 | — | — | US | claimed |
| US-20250127925-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | HERCULES CAPITAL, INC. | 2025-04-24 | — | — | US | disclosed |
| US-12076418-B2 | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo | ENGENE, INC. (CA) | 2024-09-03 | — | — | US | disclosed |
| US-20230151394-A1 | BIOLOGIC SYNTHESIS OF DIOLS FROM AMINO ACIDS | Taizhou Simplu Technology Co., Ltd. (CN) | 2023-05-18 | — | — | US | disclosed |
| EP-4127197-A1 | BIOLOGIC SYNTHESIS OF DIOLS FROM AMINO ACIDS | Taizhou Simplu Technology Co., Ltd. (CN) | 2023-02-08 | — | — | EP | disclosed |
| US-20220133907-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | HERCULES CAPITAL, INC. | 2022-05-05 | — | — | US | disclosed |
| EP-3970697-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | Engene, Inc. (CA) | 2022-03-23 | — | — | EP | disclosed |
| US-11167045-B2 | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo | HERCULES CAPITAL, INC. | 2021-11-09 | — | — | US | disclosed |
| WO-2021198273-A1 | BIOLOGIC SYNTHESIS OF DIOLS FROM AMINO ACIDS | TECHNISCHE UNIVERSITÄT HAMBURG (DE) | 2021-10-07 | — | — | WO | disclosed |
| CN-103209973-A | Lactyllactate/salt synthesis using dilactide | CARAVAN INGREDIENTS INC | 2013-07-17 | — | — | CN | disclosed |
| US-20090074697-A1 | Use of monosaccharides and disaccharides as complete replacements for synthetic fixative and styling polymers in hair styling products | HENKEL AG & CO. KGAA | 2009-03-19 | — | — | US | disclosed |
| US-6455742-B1 | LOW PRESSURE HYDROGENATION OF LACTIC ACID OR GLYCOLIC ACID TO ETHYLENE GLYCOL OR 1,2-PROPANEDIOL IN THE PRESENCE OF WATER, HYDROGEN AND COPPER SUPPORTED ON SILICA; CATALYSIS | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2002-09-24 | — | — | US | disclosed |
| US-6441241-B1 | CONTACTING WITH A CATALYST COMPRISING ZERO VALENT COPPER IN THE PRESENCE OF HYDROGEN | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2002-08-27 | — | — | US | disclosed |
| US-20020087035-A1 | Method for catalyticallly reducing carboxylic acid groups to hydroxyl groups in hydroxycarboxylic acids | WISCONSIN ALUMNI RESEARCH FOUNDATION. | 2002-07-04 | — | — | US | disclosed |
| WO-2001016063-A1 | METHOD FOR CATALYTICALLY REDUCING CARBOXYLIC ACID GROUPS TO HYDROXYL GROUPS IN HYDROXYCARBOXYLIC ACIDS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2001-03-08 | — | — | WO | disclosed |
| EP-0249222-B1 | RADIATION CURABLE RESIN | Toyo Boseki Kabushiki Kaisha (JP) | 1993-01-20 | — | — | EP | disclosed |
| US-4734480-A | MAGNETIC TAPES, ACRYLATED POLYURETHANES | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 1988-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127925-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | CSGALNACT1, CHI3L2, LNPEP | TET2 420/4885KDM4A 1237/4885KDM4C 1496/4885 |
| US-11167045-B2 | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo | CSGALNACT1, CHI3L2, LNPEP | TET2 420/4885KDM4A 1237/4885KDM4C 1496/4885 |
| US-12076418-B2 | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo | CSGALNACT1, CHI3L2, LNPEP | TET2 420/4885KDM4A 1237/4885KDM4C 1496/4885 |
| US-20220133907-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | CSGALNACT1, CHI3L2, LNPEP | TET2 420/4885KDM4A 1237/4885KDM4C 1496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.